Sequus regulatory update

SEQU withdrew its Supplemental NDA to expand the indication for Amphotec amphotericin B to include treatment

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE